Alembic FDA Wednesday, June 5, 2019 +0.30 Positive

FDA Approves CARBIDOPA AND LEVODOPA — Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited announced the approval of its Abbreviated New Drug Application for Carbidopa and Levodopa, signaling a strategic expansion in the oral Parkinson’s therapy market and intensifying competition against branded market leaders. This ANDA approval positions the manufacturer to supply the generic with the potential to capture significant market share following the expiration of patent protections.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed